European Journal of Neurology

Papers
(The H4-Index of European Journal of Neurology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
132
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy95
94
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities93
Prioritization process for European Academy of Neurology clinical practice guidelines83
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study82
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study73
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study67
Neuropathy in GAA‐FGF14 Late‐Onset Cerebellar Ataxia (SCA27B): Prevalence and Characteristics66
Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis65
Concerns Regarding “Small Fiber Morphology and Function in Inclusion Body Myositis—A Multimodal Assessment Including Confocal Corneal Microscopy”62
COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition61
Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study59
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report58
The effect of influenza vaccination on the rate of dementia amongst older adults58
Issue Information57
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy52
Central nervous system crystal‐storing histiocytosis: A case report and literature review50
ePoster49
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis48
Diagnostic accuracy of nerve excitability and compound muscle action potential scan derived biomarkers in amyotrophic lateral sclerosis47
Lessons from the past to understand the future47
Risk factors, neuroimaging correlates and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment46
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients46
Neurovascular Involvement in Fibromuscular Dysplasia: A Clue for Reappraisal of Old Classifications45
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients44
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome43
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy43
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift41
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage41
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study41
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease40
Comparative features and outcomes of major neurological complications of COVID‐1940
Long‐term MRI changes in a patient with Kelch‐like protein 11‐associated paraneoplastic neurological syndrome40
The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective38
Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta‐analysis of randomized controlled trials38
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life38
A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis38
0.21962785720825